| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | GeneticVariation | disease | BEFREE | The discrepancies found in this study indicate the variant rs34090186 in the MC1R gene, some variants of which were reported to be related to increased risk of PD and melanoma, may play a risk role in ET, confirming a potential association between ET and PD. | 30252209 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | Together with its established role in melanoma, MC1R may represent a common pathogenic pathway for melanoma and Parkinson disease.Ann Neurol 2017;81:395-406. | 28019657 | 2017 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Our results suggest that variants in MC1R do not play a major role in PD in the Chinese population. | 27084066 | 2016 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | The present study does not support a role for the MC1R p.R160W and other variants in susceptibility for PD or RBD. | 27131830 | 2016 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Our data suggest that none of the three variants of the MC1R gene and related haplotypes be associated with sporadic form of PD in Chinese Han population from Mainland China. | 26628245 | 2016 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | We found that the MC1R variant p.R160W (rs1805008) is marginally associated with PD (odds ratio = 2.10, gender- and age-adjusted p = 0.009, Bonferroni-corrected p = 0.063). | 25631192 | 2015 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | The risk for PD in carriers of two MC1R variants was markedly lower (OR=0.213, 95% CI 0.063-0.725) compared with individuals with no MC1R variant (p=0.013). | 25284244 | 2014 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Furthermore, we observed that a carrier of the founder CDKN2A [p.Leu113Leu;p.Pro114Ser] mutation as well as two MC1R moderate-risk variants, [p.Arg151Cys(+)p.Arg163Gln] developed 22 primary melanomas in the three years that followed initiation of levodopa therapy for Parkinson's disease. | 17492760 | 2007 |